LAG3 rs870849 may be a prognostic response marker in R/R DLBCL treated with glofitamab.

Therapeutic management followed an early, aggressive strategy, frequently utilizing cyclophosphamide (45.8%) and methotrexate (37.5%), with Janus kinase (JAK) inhibitors or rituximab employed in refractory cases. The observed dissociation between low CK/CRP and elevated LDH underscores the necessity for a high index of suspicion, with LDH serving as a superior marker for disease activity. While ILD presents a significant risk, early and intensive multi-modal intervention may yield superior survival outcomes in European patients compared to the historical mortality rates reported in Asian cohorts.

P4, N=5, Enrolling by invitation, University of California, San Francisco | Recruiting --> Enrolling by invitation | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027

P2, N=30, Recruiting, Hospital for Special Surgery, New York | Trial primary completion date: Jun 2025 --> Jun 2026

P2, N=60, Not yet recruiting, Sun Yat-sen University

P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

Treatment with methylprednisolone pulses followed by oral prednisolone, rituximab, and plasmapheresis led to improved kidney function and a tailored rituximab maintenance regimen was followed...Dialysis was avoided, but renal function only partially recovered. This case suggests that AAV can develop after HSCT and GVHD and highlights the importance of long-term follow-up and further research into underlying mechanisms.

High plasma cell-like phenotype signatures were linked to poorer progression-free survival (PFS) but greater benefit from R-CHOP plus bortezomib, while low-signature patients achieved better PFS with R-CHOP alone. These findings characterize the transcriptomic features of distinct plasma cell-like phenotypes in DLBCL, providing new insights into its prognostic relevance and potential for individualized treatment strategies.

P1, N=30, Recruiting, Hinge Bio

P2/3, N=89, Recruiting, Centre Hospitalier Universitaire De Nice | Not yet recruiting --> Recruiting

P3, N=200, Recruiting, Ou Bai, MD/PHD

P=N/A, N=340, Completed, Hannover Medical School | Recruiting --> Completed | N=75 --> 340 | Trial completion date: Dec 2026 --> Dec 2025